Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases
Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases
复制标题
DOI：
10.1159/000200022
复制
发表时间：
2009-01-01
期刊：
影响因子：
3.1
通讯作者：
Collantes, Eduardo
中科院分区：
文献类型：
--
作者：
Feijoo, Montserrat;Tunez, Isaac;Collantes, Eduardo
本研究评价了英夫利西单抗对慢性炎性关节病髓过氧化物酶（MPO）浓度的影响。18例患者分为活动组和非活动组。在输注英夫利西单抗前后测量红细胞沉降率、C反应蛋白、白色血细胞计数、MPO浓度和氧化应激生物标志物。活动性疾病患者的MPO和氧化生物标志物浓度升高，但抗氧化参数降低。英夫利西单抗治疗后，炎症参数和MPO浓度均恢复正常。最后总结：（1）MPO浓度与炎症活动相关，可能在这些疾病中存在的氧化应激的维持和爆发中发挥重要作用，（2）英夫利昔单抗抑制MPO浓度。版权所有（C）2009 S. Karger AG，巴塞尔
The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration. Copyright (C) 2009 S. Karger AG, Basel